Acasti Pharma Q1 2025 EPS $(0.24) vs $(0.54) YoY
Portfolio Pulse from Benzinga Newsdesk
Acasti Pharma reported its Q1 2025 earnings per share (EPS) of $(0.24), an improvement from $(0.54) year-over-year.
August 09, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acasti Pharma reported a significant improvement in its Q1 2025 EPS, reducing its loss to $(0.24) from $(0.54) year-over-year.
The improvement in EPS indicates better financial performance and cost management, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100